While the evidence on a contribution of NLRP3 to glucose metabolism, AT inflammation and atherosclerosis is clear, in the context of NAFLD, which in 20% of the cases progresses to a condition of chronic liver inflammation (non-alcoholic steatohepatitis, NASH) [191,192,193], the data are less consistent. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.